Masimo (NASDAQ:MASI) Receives Buy Rating from Stifel Nicolaus

Masimo (NASDAQ:MASI)‘s stock had its “buy” rating reiterated by analysts at Stifel Nicolaus in a note issued to investors on Friday,Benzinga reports. They presently have a $190.00 price target on the medical equipment provider’s stock, up from their prior price target of $170.00. Stifel Nicolaus’ target price would suggest a potential upside of 11.23% from the company’s current price.

A number of other equities research analysts also recently issued reports on MASI. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Wells Fargo & Company boosted their target price on Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Piper Sandler raised their price target on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price for the company in a research report on Wednesday, November 6th. Finally, BTIG Research increased their price target on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $167.00.

Masimo Price Performance

MASI stock traded up $1.69 during trading hours on Friday, hitting $170.81. 128,215 shares of the stock traded hands, compared to its average volume of 673,888. The stock has a 50-day simple moving average of $142.28 and a 200 day simple moving average of $127.76. The company has a market cap of $9.15 billion, a P/E ratio of 118.05 and a beta of 0.97. Masimo has a one year low of $91.60 and a one year high of $173.90. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same period in the prior year, the business earned $0.63 earnings per share. The business’s quarterly revenue was up 5.4% on a year-over-year basis. Equities analysts forecast that Masimo will post 4.04 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. NBC Securities Inc. boosted its stake in shares of Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 73 shares during the period. MML Investors Services LLC increased its holdings in shares of Masimo by 4.9% in the third quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 96 shares during the last quarter. Fifth Third Bancorp raised its position in shares of Masimo by 16.4% in the second quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock valued at $88,000 after purchasing an additional 98 shares during the period. Oak Thistle LLC lifted its stake in shares of Masimo by 5.2% during the 2nd quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock worth $262,000 after buying an additional 103 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 111 shares during the period. 85.96% of the stock is currently owned by institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.